As House Passes PFAS Action Act, BioLargo Takes Next Step in Commercializing Its PFAS Treatment System

BioLargo begins testing spring waters from potential customers with its PFAS treatment technology

WESTMINSTER, CA / ACCESSWIRE / July 26, 2021 / BioLargo, Inc. (OTCQB: BLGO), a sustainable technology developer and full-service environmental technology company, announced that two prospective customers (a large Southern California community and a federal agency) are providing PFAS-contaminated water samples using the AEC water treatment system treated by BioLargo. This is the first step in BioLargo’s multi-phase commercial approach: (1) off-site treatment of customer-supplied water, (2) on-site pilot treatment, and (3) full operation. In this first step, BioLargo receives contaminated water from the customer, evaluates it for operational optimization, treats the water to remove the PFAS chemicals and then has an independent laboratory analyze the treated water to confirm that the PFAS has been removed according to customer specifications. Essentially, it is a “proof of concept” phase to give the customer confidence in the next phase. Based on a successful first phase, these agencies have asked for suggestions for a pilot on site in order to confirm the success of the treatment on a larger scale at the customer’s location. Once piloting is complete, BioLargo would offer each customer bespoke systems on a commercial scale.

Randall Moore, President of BioLargo Engineering, Science & Technologies, said, “By treating the customer’s water through our in-house AEC system, we can optimize it for the unique properties of the water from each source and confirm to the customer that our system removes PFAS the level that corresponds to their respective regulatory requirements. ‘

The AEC (Aqueous Electrostatic Concentrator) is BioLargo’s proprietary water treatment technology specifically designed to remove PFAS (per- and polyfluoroalkyl substances), a group of man-made chemicals that will forever be of great concern (learn more about PFAS in our blog post.) here: https://bit.ly/3jmIyWN), from water and soil.

On July 21, 2021, the House of Representatives passed the “PFAS Action Act of 2021”. The bill, introduced by a bipartisan coalition in March 2021, would set a national drinking water standard for selected PFAS chemicals under the Safe Drinking Water Act, designating them as hazardous chemicals (so the EPA can clean contaminated sites and create stricter rules for handling them). they under CERCLA), limit industrial discharges under the Clean Water Act, and allocate $ 200 million annually to help water utilities and treatment facilities remove PFAS chemicals from their water. The bill would also restrict the incineration of PFAS-containing waste under the Clean Air Act, which could severely limit the use of the most common treatment strategy, carbon filtering followed by coal burning.

BioLargo’s AEC technology has been shown to remove more than 99% of the PFAS from contaminated water and, compared to carbon filter systems, generate about a tenth of the PFAS-laden waste and cost less to run. Less waste minimizes the environmental and regulatory impacts associated with water treatment.

Tonya Chandler, Director of Strategic Marketing and Business Development at BioLargo, said, “With the House of Representatives passing the PFAS Action Act 2021, PFAS regulations are imminent. BioLargo is in a perfect position to bring its revolutionary PFAS removal system to market. The AEC produces significantly less waste than traditional systems, making it a superior solution in this regulatory environment. ‘

Learn more about BioLargo’s AEC treatment through its engineering department at www.biolargoengineering.com/biolargo-aec

Contact Tonya Chandler for more information or to make an appointment at [email protected].

About BioLargo, Inc.
BioLargo, Inc. (OTCQB: BLGO) invents, develops and commercializes innovative platform technologies to solve demanding environmental problems such as PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control and infection control. With over 13 years of extensive research and development, BioLargo holds a wide range of issued patents, maintains a robust product pipeline, and offers comprehensive environmental engineering. Our peer-reviewed scientific approach enables us to invent or acquire new technologies and develop them to maturity through our operating subsidiaries. With a strong focus on collaborations with academic, municipal and commercial organizations and associations, BioLargo has proven itself with over 80 grants and numerous pilot projects. We monetize through direct sales, recurring service agreements, license agreements, strategic joint venture formation and / or the sale of intellectual property. See our website at www.BioLargo.com.

Contact information
Dennis P. Calvert
President and CEO of BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, those about BioLargo’s (the “Company”) expectations with respect to anticipated plans for future operations. These statements involve risks and uncertainties and actual results could differ materially from future results expressed or implied in the forward-looking statements. The risks and uncertainties include, without limitation: the impact of the COVID-19 pandemic on the company’s business, results of operations, financial condition, and share price; the impact of regional economic conditions on the company’s business, including the impact on consumer and corporate purchasing decisions; the company’s ability to compete in markets that are highly competitive and subject to rapid technological change; the company’s ability to manage frequent launches and transitions of products and services, including making them available in the marketplace and driving customer demand for new products, services, and technological innovations on a timely basis; the company’s dependence on the performance of distributors of the company’s products. For more information about these risks and other potential factors that could affect the company’s business and financial results, see the SEC filings, including the sections “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations “. the company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The company assumes no obligation to update any forward-looking statement or information, whichever date may apply.

SOURCE: BioLargo, Inc.

View source version on accesswire.com:
https://www.accesswire.com/656954/As-House-Passes-PFAS-Action-Act-BioLargo-Takes-Next-Step-in-Commercializing-Its-PFAS-Treatment-System